Expression and binding properties of two isoforms of the human growth hormone receptor  by Sobrier, Marie-Laure et al.
Volume 3 19, number 1,2, 16-20 FEBS 12164 
0 1993 Federation of European Biochemical Societies 00145793/93/$6.00 
March 1993 
Expression and binding properties of two isoforms of the human growth 
hormone receptor 
Marie-Lam-e Sobrier, Philippe Duquesnoy, BknCdicte Duriez, Serge Amselem and Michel Goossens 
Laboratoire de GknPtique Mokulaire, Institut National de la SantP et de la Recherche MPdicale U.91, H6pital Henri Mondor, 94010 
CrCteil, France 
Received 8 January 1993 
Two rsoforms of the human growth hormone receptor mRNA, one containing exon 3 (encoding an extracellular domam of the receptor), hGHR. 
and one excluding exon 3, hGHRd3, have been described. To study the cellular distribution of the two types of messengers we have analysed a 
panel of tissues. Both isoforms were expressed independently or srmultaneously depending on the tissue studied. To investigate the binding 
properties of hGHRd3 we have cloned its cDNA in a eukaryotic expression vector; transient expression in COS-7 cells showed that the receptor 
without exon 3 was expressed on the plasma membrane and was able to bmd human growth hormone (hGH) with the same high affinity as hGHR. 
Human lactogen (hCS) removed lz51-hGH bound to the full-length and exon 3 - excluding receptors to the same extent. These results show that 
hGHR and hGHRd3 have tissue-specific expression and share identical binding properties for hGH and hCS and leave open the possibility that 
exon 3 might influence receptor signalling. 
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1. INTRODUCTION 
Growth hormone (GH-N) is synthesized and secreted 
from the anterior pituitary lobe, and has multiple effects 
on both cells and the organism as a whole. They include 
promotion of body growth, stimulation of intermediary 
metabolism [l], and transcriptional regulation of spe- 
cific genes (IGF-I and cytochrome P450 [2], c-fos and 
c-&n [3]). GH-N belongs to a family of proteins includ- 
ing the GH variant expressed in the placenta (GH-V) 
and chorionic somatomammotropin hormones (hCS-A 
and hCS-B). These forms of hGH are encoded by differ- 
ent genes (GH-N, GH-V, CS-A and CS-B) clustered on 
the short arm of chromosome 17. In addition, alterna- 
tive splicing of the same transcript can generate differ- 
ent isoforms (GH-N 22 kDa, 20 kDa or 17.5 kDa) (for 
review, see [4]). These proteins have different metabolic 
properties; for example, the growth-promoting effect of 
hGH-V is similar to that of hGH-N whereas its lacto- 
genie activity is lower [5]. It is now generally accepted 
that these hormones act on target cells through specific 
binding to the extracellular domain of transmembrane 
receptors. Although receptors for GH (GHR) are pres- 
ent in many cell types, an important question is whether 
a single GH receptor mediates the multiple effects of 
GH or whether different receptors exist. Various ap- 
proaches, including direct radioligand studies using a 
panel of monoclonal antibodies [6]. have provided evi- 
dence supporting the existence of membrane GH recep- 
tor subtypes. A cell-surface receptor was first cloned in 
rabbits and man [7] through its ability to bind to hGH- 
N 22 kDa with high affinity. Comparison of the primary 
sequences of GHR and related receptors isolated estab- 
lished that they were members of the new cytokine re- 
ceptor family including receptors for prolactin, erythro- 
poietin, granulocyte/macrophage colony-stimulating 
factor, interleukin-2, -3, -4, -5, -6, -7 and interferons [8] 
and, more recently, the receptors for IL-9 [9] and ciliary 
neurotrophic factor [lo]. Structural and functional anal- 
yses of GHR should help to elucidate the different spe- 
cific transducing pathways and the mechanisms by 
which GH binding initiates cellular responses. 
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The extracellular part of the receptor molecule is en- 
coded by exons 2 to 7, which specify 244 of the 246 
amino acids of the extracellular domain of the mature 
hGHR. Godowski et al. [l l] have reported several 
GHR cDNA clones that diverge within the coding re- 
gion. In one of these, the exon 3 sequence is missing. 
More recently, Urbanek et al. [12] showed that the ex- 
pression of the human GH receptor isoform is predicted 
by tissue-specific alternative splicing of exon 3, and that 
the exon 3-excluding GHR is the single isoform ex- 
pressed in the placental villi. The deletion of exon 3 
gives rise to a 224-amino-acid exoplasmic domain, con- 
taining an aspartic acid in place of the alanine 24 at the 
exon 24 junction. Although the genomic organization 
has been only characterized in man, the striking conser- 
vation of this protein through evolution supports the 
hypothesis that exon junctions map to the equivalent 
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Fig. 1. Sequence alignment of the first 60 amino acids of the human (hu), porcine (PO), rabbit (rb), ovine (oY), bovine (bo), mouse (mo), rat (rt) 
and chicken (ch) of the growth hormone receptor (GHR). This alignment was derived using the CLUSTAL program in CITI ZBISANCE (Dessen, 
1990). Exon junctions are based on the conservation of the human GH receptor sequence. At the exon junctions, nucleotide sequences are noted 
in small letters whereas amino acids are in bold. The change in amino acid resulting from exon 3 splicing is indicated on the right. (*), conservation 
of amino acid in all species. 
locations in all species. The corresponding exon 3-ex- 
&ding isoform in pigs [13], rabbits 1’71, cows [14] and 
sheep iiS] apparently contain an asp&ate at position 
24, whereas an alanine is found at this position in the 
exon 3-containing isoform (Fig. 1). However, in rats 
[16] and mice [17], exon 3 splicing gives rise to a glycine 
in place of alanine. Interestingly, in chickens [18], in 
which the only cDNA cloned lacks exon 3, the residue 
present at the corresponding position is also an aspar- 
tate (Fig. 1). These observations raised the question as 
to whether this alte~ative inclusio~exclusion causes 
differences in hormone binding or signal transduction. 
To elucidate the role of these isoforms, we studied the 
distribution of the two mRNAs in various tissues and 
analysed the abilities of the receptors, expressed in vitro, 
to bind hormones of the GHlCS family. 
2. MATERIALS AND METHODS 
2.1. RNA preparation and cDNA synthesis 
Total cellular RNA was isolated from tissues, primary tissue culture 
cells and cell lines by means of guanidium thiocyanate phenol/chloro- 
form extraction [19]. For PCR assays, 10 pug of total RNA was first 
reverse-transcribed into cDNA with hexanucleotides a  primers (Phar- 
macia) and 40 LJ of AMV reverse transcriptase (Promega). One tenth 
of the reverse reaction product was used for amplification with prim- 
ers PF (S-~CCATGTCGACCTACAGGTAT~ATCTCTGG-~), 
located just upstream of exon 2, and PV (S-CCACCATTGCTA- 
GTTAGCTT-3’), located in the middle of exon 5, that provides a 
420-bp fragment with exon 3 and a 3%bp fragment without exon 3. 
PCR was performed essentially according to the Perkin-ElmeKetus 
Thermus aquaticus polymerase protocol. 
2.2. Plasmid construction 
The full-length cDNA of the human growth hormone receptor has 
been previously cloned in the expression vector pECE 1201; the plasmid 
was named phGHRwt. 
To obtain the exon 3-defeted form, recombinant PCR was per- 
formed, as described by Higuchi [21] on plasmid phGHRwt. As the 
sall and EcoRV cleavage sites are unique in the hGHR cDNA se- 
quence and absent from the expression vector pECE, it was possible 
to remove the fragment with exon 3 from phGHRwt and to replace 
it with the amplified segment with exon 3 deleted. The plasmid was 
named phGHRd3. 
2.3. Transfection of expression vector into eukaryotic ceiis 
Sixty-percent-confluent COS-7 monkey kidney ceils were trans- 
fected by the lipof~tin method (GibcolBRL, Life T~hnoIo~, Grand 
Island, NY) with 2 pg of phGHRwt or phGHRd3 according to the 
manufacturer’s instructions. After 48 h of expression the confluent 
monolayers were serum-privated for 12 h before being processed for 
binding studies. 
2.4. Binding assays 
COS-7 cells were scraped in 1 ml of phosphate-buffered saline and 
lysed in Eppendorf tubes by three freeze-thaw cycles. Total particulate 
membrane fraction was prepared by centrifugation for 30 min at 
1,500 x g. The pellets were resuspended in 25 mM Tris-HCI, pH 7.4, 
20 mM MgCI,. One hundred micrograms of protein and 100,~ cpm 
of ‘“%-labeled hGH (“%hGH) per tube were used for binding 
studies. 
For Scatchard analyses, membranes were incubated with various 
amounts of unlabelled hGH. After incubation for 12 h at 4°C the 
mixtures were filtered through 0.22 pm GV membranes (Millipore), 
washed in 50 mM Tris, pH 7.4, 1 mg/mI bovine serum albumin. The 
amount of radioactivity was measured in a g counter. All determina- 
tions were done in triplicate. Human proiactin (hPRL) and human 
lactogen (hCS) (Sigma) were used as ligands for constructing compe- 
tition curves. Two micrograms of hGH was labelled with 200 &I of 
lZ51 (1Ci = 37 GBq) (IMS 30. Amersham) as described elsewhere 1221. 
A specific activity of 3&60 /*Ci/pg was obtained. 
3. RESULTS 
3.1. E~pres~i#n pattern of the g~~~t~ hormone receptor 
messenger RNA 
A wide variety of tissues were tested for the presence 
or absence of exon 3 in the human GH receptor mRNA. 
Total RNA was reverse transcribed and then amplified 
using primers PF and PV as described in Section 2. Fig. 
2 shows the electrophoresis patterns of RT-PCR prod- 
ucts. In each tissue, a semi-quantitative stimation of 
the relative proportion of both isoforms was made by 
inspecting the geIs. 
The three bands observed include a small fragment 
(354 bp) corresponding to the hGHRd3 species, a larger 
fragment (420 bp) corresponding to hGHR, and a 
slowly migrating segment. This latter band consists of 
heteroduplexes generated by the single-stranded reasso- 
17 
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Fig. 2. Ethidium bromide stained gel of tissue distribution of hGHR and hGHRd3. RT/PCR analysis of the exon 3 splicing pattern of hGHR 
transcripts in primary cultures of human cytotrophoblast cells (C), primary culture of human syncitiotrophoblast cells (S), human stomach 
(stomach), total human placenta (placenta), B lymphocytes transformed with Epstein Barr virus (lymphocytes), human breast (breast), primary 
cultures of human keratinocytes (keratinocytes), adult human liver (liver). human hepatoma-derived cell line (HepG2), human brain (brain), human 
prostate (prostate), human lung (lung), human adipose tissue (adipose tissue), primary cultures of human fibroblasts (fibroblasts), (H) heteroduplex 
form amplified with PF and PV primers, (L) one-Kb ladder from GrbcolBRL Life Technology. (I)-heteroduplex formed with the two different 
single strands, (2)-420bp which corresponds to hGHR, (3)- 354bp which corresponds to hGHRd3. 
ciation of the 354 and 420 bp fragments; indeed, when 
this DNA was removed from the gel and amplified with 
the same primers, the three species were generated in 
same proportions (Fig. 2, lane H). The use of primers 
able to generate heteroduplexes enhances the sensitivity 
of detection of both isoforms: the presence of heterodu- 
plexes on a gel indicates the existence of both isoforms 
in the sample studied, even if one of the homoduplexes 
is not visible. 
Five electrophoretic patterns were observed. (i) Only 
one isoform without exon 3 was expressed in the synci- 
tiotrophoblast and cytotrophoblast. (ii) Both isoforms 
were found in the stomach, but the deleted isoform was 
predominant; the presence of the other undetected 
isoform is revealed by the heteroduplex. (iii) The two 
messenger RNAs showed the same level of expression 
in total placenta, EBV-transformed lymphocytes, 
breast, keratinocytes, liver, the HepG2 cell line and the 
brain. (iv) The isoform containing exon 3 was mainly 
expressed in the prostate and lung. (v) In adipose tissue 
and cultured fibroblasts, only the hGHR isoform was 
expressed. 
3.2. Determination of the relative association constant 
and binding specl$city of hGHRd3 and hGHR 
GHR-cDNA lacking exon 3 was cloned as described 
in Section 2. The two constructs, phGHRwt and 
phGHRd3, were then transiently expressed in COS-7 
cells. Binding studies were performed on cell mem- 
branes using “‘1-hGH. The association constant of 
hGHR and hGHRd3 were calculated from the 
Scatchard plot as 2.0 nM_’ and 2.8 nM_‘, respectively 
(Fig. 3). 
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Human prolactin (hPRL) and human lactogen (hCS) 
were assayed for their ability to displace hGH bound to 
the two receptor isoforms. The results confirmed that 
hPRL did not bind to hGHR. This hormone was also 
unable to displace hGH bound to hGHRd3. In con- 
trast, hCS showed some affinity for hGHR, and similar 
results were obtained with cells transfected with 
phGHRd3 (Fig. 3). 
4. DISCUSSION 
Exons 2 to 7 of the human GH receptor (hGHR) gene 
have been shown to encode the exoplasmic domain of 
the protein. However, Godowski et al. [l I], who studied 
hGHR cDNA clones derived from a human liver cDNA 
library, found that alternative splicing at the 5’ end of 
the hGHR transcripts could generate two receptors 
isoforms, one containing (hGHR) and the other exclud- 
ing exon 3 (hGHRd3). This was recently confirmed by 
Urbanek et al. [12], who characterized the hGHRd3 
species as the unique GH receptor isoform expressed in 
the placental villi. Given that the biological activities of 
GH depend on its target cells, an important question is 
whether or not these isoforms have the same metabolic 
functions. We have previously shown that the GHR 
gene is genetically linked to a hereditary GH-insensitiv- 
ity condition (Laron syndrome, reviewed in [23]), 
thereby demonstrating that the receptor is indeed in- 
volved in growth [24]. However, since all the mutations 
discovered so far in affected families have been located 
outside exon 3 and within exons that are common to 
hGHR and hGHRd3 [I 1,20,25,26], they would result in 
sequence abnormalities in both isoforms, making it im- 
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Fig. 3. Expression of hGHR and hGHRd3 cDNA clones in COS-7 
cells. Binding of I”-I-hGH to membranes from CO.%7 cells transfected 
with phGHRwt (A) or phGHRd3 (B). Plasma membranes (100 pg) 
were incubated with “‘-I-hGH (100,000 cpm) and various concentra- 
tions of native hGH (n) and hCS (u). hPRL (I) was added in excess 
(2 ,ug). @se?) Scatchard plot of the competition assay with unlabeled 
hGH. B/F, bound to free ratio. 
possible to correlate one isoform with a particular func- 
tion. In this study, to elucidate the respective roles of 
hGHR and hGHRd3, we first looked at their tissue 
distribution, One or both isoforms were detected, de- 
pending on the tissue analysed. The expression pattern 
was similar to that reported by Urbanek et al. [12], with 
some exceptions. In particular, we confirmed that total 
placenta contains both isoforms, whereas fetal placenta 
cells (syncitiotrophoblast and cytotrophoblast cells) ex- 
press the hGHRd3 form only. However, in contrast to 
Urbanek et al. [12], who found only the hGHR form in 
liver, we clearly detected both isoforms in this tissue. No 
correlation was found between the expression of one or 
other isoform and the known metabolic functions of 
GH in the tissues analysed. For instance, GH does not 
promote cell proliferation in the brain 1271, in which the 
two isoforms are equivalently expressed, but it does so 
in the liver [27] in which both isoforms are also ex- 
pressed in the same ratio. In addition, GH promotes cell 
division in stomach where hGHRd3 is mainly expressed 
or in adipose tissue, in which only hGHR is expressed. 
Similarly, we found no correlation between the expres- 
sion pattern and the embryonal origin of the different 
tissues. 
However, studies aiming at d~iphering the role of the 
hGHRd3 isoform have been based on mRNA analysis. 
Indeed, hGHRd3 protein has never been characterized, 
raising the question as to whether hGHRd3 mRNA is 
translated and the corresponding protein transported to 
the plasma membrane. The exon 4 spliced form of IL-2 
receptor does not result in the expression of the recep- 
tors, even though specific mRNA is detected in trans- 
fected cells [2x]. To address this question in the GHR 
system, we obtained transient expression of hGHRd3 in 
COS-7 cells. hGHRd3 was found to bind GH with a 
high affinity and to have a K, value similar to that 
achieved in cells transfected with phGHRwt. These re- 
sults are similar to those obtained in a prokaryotic ex- 
pression system by Bass et al. 12911. We therefore con- 
clude that post-translational modi~~ations of the GHR 
isoforms are not critical in terms of binding activity. 
This binding result is also consistent with data obtained 
by examination of crystal structure of the complex be- 
tween GH and the exoplasmic domain of its receptor 
[30]. This later study confirmed the results of Cuning- 
ham et al. [31] who predicted that dimerization of GH 
would occur around one molecule of GH, and showed 
that the peptide encoded by exon 3 was located away 
from binding interfaces. 
Given the similar binding properties of hGHR and 
hGHRd3, we speculate that different metabolic path- 
ways are activated depending on the inclusion or exclu- 
sion of exon 3. It is striking that exclusion of exon 3 
should result in the loss of four phosphorylation sites 
and one glycosylation site and in the replacement of 
alanine 24 by an aspartate at the end of exon 2. This 
latter modification involves a highly conserved amino 
acid and leads to a change in charge, size and hydropho- 
bicity (Fig. 1). These modifications could possibly inter- 
fere with the ability of hGHRd3 to interact with a spe- 
cific protein involved in signal transduction. Thus, al- 
though hGHR and hGHRd3 exhibit similar binding 
properties, hGHRd3 may transduce a specific signal. 
This h~othesis is strengthened by studies on signal 
transduction pathways in this superfamily of receptors 
which clearly suggest he involvement of multiple pro- 
tein in receptor specifity and function [32]. 
No receptor for hCS has yet been identified. How- 
ever, given the lactogenic activity of both this hormone 
and prolactin, this latter hormone acting through a spe- 
cific and homologous receptor which lacks exon 3 1331, 
we tested CS and PRL binding to hGHRd3. Interest- 
ingly, hCS displaced hGH from both hGHRd3 and 
hGHR to a similar degree; however, PRL did not bind 
to either receptor. For the two types of receptor a high 
concentration of hCS (about 0.2 PM) is necessary to 
displace bound hGH; this result may be related to the 
very high level of hCS mRNA and protein observed in 
19 
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total placenta at term of pregnancy (lo-20% of the total 
placenta mRNA) [34]. 
Finally, since hGHRd3 is the only isoform expressed 
in fetal placenta cells and hGH-V is also produced ex- 
clusively by the placenta, it would be of interest to 
analyse the binding of hGH-V to hGHR and hGHRd3. 
Our understanding of these GHR isoforms should im- 
prove with the availability of appropriate functional 
assays to investigate signal transduction. 
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